The care of patients with cholestatic liver diseases such as primary sclerosing cholangitis (PSC) is challenging, partly due to the lack of knowledge ...
The care of patients with cholestatic liver diseases such as primary sclerosing cholangitis (PSC) is challenging, partly due ...
Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC). Iqirvo ...
Nebokitug is a lab-engineered antibody that targets a molecule called CCL24, a signaling protein known to drive inflammation ...
Researchers have reported encouraging results from a clinical trial of a new monoclonal antibody therapy for primary ...
PSC occurs in 1 out of 10,000 people, who are mostly male adults between 30 and 60 years old, and it commonly develops in patients with inflammatory bowel disease who have ulcerative colitis. The lack ...
A new monoclonal antibody treatment has shown promising results for a rare liver disease called primary sclerosing ...
A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...
USA: A large retrospective, propensity score–matched cohort study found that ursodeoxycholic acid (UDCA) use in patients with ...
Using electronic health record data from more than 12,000 PBC patients, investigators found that UDCA use was associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback